metricas
covid
Medicina Clínica (English Edition) Cost-per-responder analysis comparing romiplostim to rituximab in the treatment ...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain
Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España
M. Fernanda Lópeza, María Eva Mingotb, David Valcárcelc, Vicente Vicente Garcíad, Allison Perrine, Ignasi Campos Tapiasf,
Corresponding author
ignasic@amgen.com

Corresponding author.
a Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
b Hospital Regional Universitario Carlos Haya, Málaga, Spain
c Hospital Vall d’Hebron, Barcelona, Spain
d Hospital Universitario Morales Meseguer, Murcia, Spain
e LA-SER Analytica, Nueva York, United States
f Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland
Read
73
Times
was read the article
14
Total PDF
59
Total HTML
Share statistics
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 10 0 1 1
2023 3 3 2 5
2017 10 4 1 5
2017 9 8 2 10
2017 8 11 1 12
2017 7 11 4 15
2017 6 10 2 12
2017 5 12 1 13

Follow this link to access the full text of the article